ALDH1A1 and cancer: Our data suggests that therapeutics based on SIRPα Ig domains that bind to CD47 have the potential to enhance cancer stemness in triple negative breast cancer cells as evidenced by increasing spheroid formation, cell proliferation and ALDH1 expression, which is a universal marker for stem and progenitor cells and also associated with poor prognosis in triple negative breast cancer (Panigoro et al., 2020).